Prejsť na hlavný obsah
European Health and Digital Executive Agency (HaDEA)
  • Výzva na predkladanie návrhov
  • Otvorené

Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections

Podrobnosti

Stav
Otvorené
Referencia
HORIZON-HLTH-2025-01-DISEASE-01
Dátum uverejnenia
21. mája 2025 v Funding and Tenders Portal
Deň otvorenia
Druh termínu
Jednofázový
Lehota (dátum)
16. septembra 2025, 17:00 (CEST)
Programme Sector
  • Health
Programme
  • Horizon Europe
  • Horizon Europe Cluster 1: Health

Opis

Under the topic HORIZON-HLTH-2025-01-DISEASE-01 should aim to deliver results that are directed, tailored towards and contributing to most of the following expected outcomes:

  • Researchers and developers make the best use of the state-of-the-art knowledge and resources for an effective development of new treatment options for patients suffering from difficult-to-treat infections.
  • Healthcare professionals and people living with difficult-to-treat infections are ultimately provided with the availability of clinically useful phage therapies.
  • Regulators are provided with quantifiable, verifiable and replicable data on safety and efficacy of phage therapy for human use and move faster towards market approval of novel phage-based therapies against antimicrobial resistant infections.
  • Citizens are engaged and informed on innovative phage-based treatments as alternative therapeutic options complementary to antibiotics.

Interested parties can find more information and apply on the Funding and Tenders Portal.